Actively Recruiting
R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
Led by University Health Network, Toronto · Updated on 2025-12-19
25
Participants Needed
1
Research Sites
453 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will investigate the safety and efficacy of using robotic retroperitoneal lymph node dissection (R-RPLND), a minimally invasive surgical approach, as the first-line of treatment for stage IIA/B (or equivalent) seminoma patients. R-RPLND will be trialed as an alternative to chemotherapy, radiation therapy (for seminoma patients) and open RPLND in this study.
CONDITIONS
Official Title
R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed seminomatous testicular germ cell tumour with negative margins on radical orchiectomy
- Lymphadenopathy in the retroperitoneum: at least one lymph node 5cm in size detected on contrast CT scan or MRI (CS IIA/B or active surveillance relapse with CS IIA/B equivalent)
- CT Chest negative for metastasis
- Initial diagnosis of clinical or stage IIA/B disease or recurrence after surveillance for clinical stage I disease
- Serum tumour marker levels within 10 days of RPLND: AFP below 2.5 times upper limit of normal and b2-hCG below 5 IU/L
- Curative treatment with RPLND is intended
- Under care of a uro-oncologist at Princess Margaret Cancer Centre
- Willing to comply with follow-up protocol
- Capable of providing informed consent
You will not qualify if you...
- Retroperitoneal lymphadenopathy larger than 5cm in the transverse plane (CS IIC)
- Metastasis to distant lymph nodes or any organ (CS III)
- History of chemotherapy or radiotherapy to the retroperitoneum
- Previous scrotal or retroperitoneal surgery for reasons other than germ cell tumour
- Reduced general condition, uncontrolled illnesses, or life-threatening disease
- Psychiatric illnesses limiting compliance with study requirements
- Unsuitable for robotic surgery as determined by treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
R
Robert Hamilton, MD
CONTACT
I
Isabelle Tan, BSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here